{
    "patient": {
        "Name": "Jasmine Hood",
        "DateOfBirth": "1960-09-25",
        "Sex": "Male",
        "Diagnosis": "Squamous cell carcinoma",
        "BodyPart": "Prostate",
        "Physician": "Dr. Rachel Wright",
        "TreatingInstitution": "Crawford and Sons"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Prostate",
            "CollectedDate": "2023-11-30",
            "ReceivedDate": "2023-11-30",
            "TumorPercentage": "65%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2023-12-07",
            "ReceivedDate": "2023-12-09"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "BRCA1",
                "DNA Alteration": "c.5265_5266insC",
                "GeneMutation": "p.E23Vfs*17 Frameshift-LOF",
                "VariantAlleleFraction": "15.0%"
            },
            {
                "Gene": "TOP2A",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.A1515S Frameshift-LOF",
                "VariantAlleleFraction": "7.18%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "ARID2",
                "DNA Alteration": " c.798G>A",
                "GeneMutation": "p.A1515S Stopgain-LOF",
                "VariantAlleleFraction": "10.79%"
            },
            {
                "Gene": "ALDH2",
                "DNA Alteration": "c.1510G>A",
                "GeneMutation": "p.A1515S Stopgain-LOF",
                "VariantAlleleFraction": "21.97%"
            },
            {
                "Gene": "DDR2",
                "DNA Alteration": "c.716T>G",
                "GeneMutation": "p.L239R Stopgain-LOF",
                "VariantAlleleFraction": "10.49%"
            },
            {
                "Gene": "ERCC2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.E504K Stopgain-LOF",
                "VariantAlleleFraction": "12.08%"
            },
            {
                "Gene": "PKLR",
                "DNA Alteration": "c.1436G>A",
                "GeneMutation": "p.F332V Spliceregionvariant-LOF",
                "VariantAlleleFraction": "1.33%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": [
            "MUTYH",
            "ALK",
            "DNMT3A",
            "PTEN"
        ]
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "2 m/Mb",
            "Tmbpercentile": "31%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "Equivocal"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "FGFR1",
                "DNA Alteration": "c.1966A>G",
                "GeneMutation": "p.K656E Frameshift-LOF",
                "VariantAlleleFraction": "6.58%"
            },
            {
                "Gene": "ARID2",
                "DNA Alteration": " c.798G>A",
                "GeneMutation": " p.W266* Spliceregionvariant-LOF",
                "VariantAlleleFraction": "18.0%"
            },
            {
                "Gene": "RNF43",
                "DNA Alteration": "c.505G>A",
                "GeneMutation": "p.A169T Nonsense-GOF",
                "VariantAlleleFraction": "8.93%"
            },
            {
                "Gene": "PIK3CA",
                "DNA Alteration": "c.1624G>C",
                "GeneMutation": "p.E545G Frameshift-GOF",
                "VariantAlleleFraction": "1.99%"
            },
            {
                "Gene": "TP53",
                "DNA Alteration": "c.743G>A",
                "GeneMutation": "p.V272M Frameshift-GOF",
                "VariantAlleleFraction": "4.02%"
            },
            {
                "Gene": "B2M",
                "DNA Alteration": "c.2T>G",
                "GeneMutation": "p.M1R Spliceregionvariant-LOF",
                "VariantAlleleFraction": "6.01%"
            },
            {
                "Gene": "EGFR",
                "DNA Alteration": "c.866C>A",
                "GeneMutation": "p.V769M Spliceregionvariant-GOF",
                "VariantAlleleFraction": "9.45%"
            },
            {
                "Gene": "STAG2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R1012X Spliceregionvariant-LOF",
                "VariantAlleleFraction": "6.99%"
            },
            {
                "Gene": "PHF6",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R225X Spliceregionvariant-LOF",
                "VariantAlleleFraction": "7.08%"
            },
            {
                "Gene": "CDKN2A",
                "DNA Alteration": "c.248_249delinsCT",
                "GeneMutation": "p.A102V Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "1.19%"
            }
        ],
        "Germline": []
    },
    "low coverage regions": [
        "CHEK2",
        "PTPN11",
        "HDAC2"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "BRCA1",
                "DNA Alteration": "c.5265_5266insC",
                "GeneMutation": "p.E23Vfs*17 Frameshift-LOF",
                "description": "BCL11B encodes a C2H2-type zinc finger protein that functions as a transcriptional repressor and plays a role in T-cell development and survival. Loss of function mutations, copy number loss, and fusions resulting in the underexpression of BCL11B are associated with cancer progression.",
                "VariantAlleleFraction": "15.0%"
            },
            {
                "Gene": "TOP2A",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.A1515S Frameshift-LOF",
                "description": "BCL11B encodes a C2H2-type zinc finger protein that functions as a transcriptional repressor and plays a role in T-cell development and survival. Loss of function mutations, copy number loss, and fusions resulting in the underexpression of BCL11B are associated with cancer progression.",
                "VariantAlleleFraction": "7.18%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "ARID2",
                "DNA Alteration": " c.798G>A",
                "GeneMutation": "p.A1515S Stopgain-LOF",
                "description": "ARID2 encodes a protein that is a subunit of the SWI/SNF chromatin remodeling complex SWI/SNF-B or PBAF. This complex functions in ligand-dependent transcriptional activation. Loss of function mutations and copy number loss of ARID2 are associated with cancer progression.",
                "VariantAlleleFraction": "10.79%"
            },
            {
                "Gene": "ALDH2",
                "DNA Alteration": "c.1510G>A",
                "GeneMutation": "p.A1515S Stopgain-LOF",
                "description": "RBM10 encodes a protein that contains a RNA-binding motif and interacts with RNA homopolymers, and is thought to function in regulating alternative splicing. Loss of function mutations and copy number loss of RBM10 are associated with cancer progression.",
                "VariantAlleleFraction": "21.97%"
            },
            {
                "Gene": "DDR2",
                "DNA Alteration": "c.716T>G",
                "GeneMutation": "p.L239R Stopgain-LOF",
                "description": "ARID2 encodes a protein that is a subunit of the SWI/SNF chromatin remodeling complex SWI/SNF-B or PBAF. This complex functions in ligand-dependent transcriptional activation. Loss of function mutations and copy number loss of ARID2 are associated with cancer progression.",
                "VariantAlleleFraction": "10.49%"
            },
            {
                "Gene": "ERCC2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.E504K Stopgain-LOF",
                "description": "RBM10 encodes a protein that contains a RNA-binding motif and interacts with RNA homopolymers, and is thought to function in regulating alternative splicing. Loss of function mutations and copy number loss of RBM10 are associated with cancer progression.",
                "VariantAlleleFraction": "12.08%"
            },
            {
                "Gene": "PKLR",
                "DNA Alteration": "c.1436G>A",
                "GeneMutation": "p.F332V Spliceregionvariant-LOF",
                "description": "NFE2L2 acts as a transcription factor for proteins that contain an antioxidant response element (ARE) within their promoter sequence. Genes that contain ARE are involved in injury and inflammation response. Activating mutations and overexpression of NFE2L2 are associated with cancer progression.",
                "VariantAlleleFraction": "1.33%"
            }
        ]
    },
    "clinical history": {
        "Date": "2023-11-26"
    },
    "other": {
        "ReportId": "4726",
        "ReportDate": "2023-12-08",
        "SignedBy": "Rachel Wright",
        "Supervisor": "Dr. Catherine Melton"
    }
}